Acticor Biotech announced on Thursday that a Phase 2/3 clinical trial had failed to meet its endpoints in the treatment of stroke, resulting in a suspension of its share price.The biopharmaceutical...
Related Keywords
Yannick Pletan , , Acticor Biotech , Chief Operating Officer , Chief Medical Officer , Markets ,
vimarsana.com © 2020. All Rights Reserved.